Overview

• Biopharmaceutical firm's Q4 revenue grew 65% yr/yr, driven by AUVELITY and SUNOSI

• Company reported net loss of $28.6 mln for Q4, narrowed from last year

• Company acquired AXS-17, expanding CNS disorder treatment pipeline

Outlook

• Axsome expects FDA action on AXS-05 for Alzheimer's agitation by April 30, 2026

• Company plans NDA submission for AXS-12 in narcolepsy in 1Q 2026

• Axsome to initiate Phase 3 trial of solriamfetol in MDD with EDS in 1Q 2026

Result Drivers

• AUVELITY SALES - AUVELITY's Q4 sales rose 68% yr/yr, driven by increased prescriptions and payer coverage

• SUNOSI REVENUE - SUNOSI's Q4 revenue grew 40% yr/yr, aided by increased prescriptions and royalty revenue

• SYMBRAVO LAUNCH - SYMBRAVO contributed $4.1 mln in Q4 sales following its recent launch

Company press release: ID:nGNX4jRcrd

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Axsome Therapeutics Inc is $220.00, about 19.7% above its February 20 closing price of $183.72

• The stock recently traded at 161 times the next 12-month earnings vs. a P/E of 1,812 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.